Navigation Links
Mayo Clinic's Dr. Ronald C. Petersen Awarded Leon Thal Prize for Excellence in Dementia Research
Date:12/4/2007

LAS VEGAS, Dec. 4 /PRNewswire/ -- Lou Ruvo Brain Institute today announced Dr. Ronald C. Petersen, Director of the Mayo Clinic Alzheimer's Disease Research Center, was awarded the Lou Ruvo Brain Institute's Leon Thal Prize for Excellence in Dementia Research. Dr. Petersen became the first recipient of the award.

This prestigious award acknowledges a senior investigator in the field of dementia research who best emulates Leon Thal's characteristics as physician, teacher, scientist, mentor, and humanitarian. Recognized by many as the world's most prominent scientist in the field of Alzheimer's disease, Dr. Leon Thal passed away earlier this year.

Lou Ruvo Brain Institute's President & CEO Zaven Khachaturian, Ph.D. presented Dr. Petersen with the award at a Monday dinner reception. The reception was part of the Leon Thal Symposium on the Prevention of Dementia, which assembled 40 of the world's foremost experts in dementia research in Las Vegas (December 2-4) to craft a roadmap for public policies that would radically change current paradigms of therapy development for dementia. In doing so, the conference is projecting Leon Thal's dream for the future -- by focusing the attention of the field on formulating new national strategies to accelerate drug discovery, development, and validation (clinical trials).

About the Leon Thal Prize

Nominees were evaluated by a peer-review panel consisting of senior opinion leaders in the field, who reviewed candidates on the following criteria:

-- Significant contribution to Rx/Dx development,

-- Selfless public service on behalf of the field,

-- Mentoring, and

-- Leadership in developing cooperative/collaborative endeavors and

promoting goodwill cooperation in the field.

"Dr. Petersen well deserves the Leon Thal Prize, not only because of his long history of significant scientific contributions to our understanding of dementia, but also for serving as
'/>"/>

SOURCE Lou Ruvo Brain Institute
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Governor Rendell Announces CHIP Enrollment Clinics at Several Rite Aid Stores
2. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
4. Blue Cross of California Invests $10.6 Million in Community Clinics Through the Investment in a Healthy California Program
5. Houston Employers Hear New Research That Supports the Case for Retail Clinics
6. Low-level Laser Therapy Clinics Partnership Targets Helping People Nationwide
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. St. Christophers Foundation For Children Ronald McDonald(R) Care Mobile Making Tri-State Visits to Provide Dental Care to Children at No Cost
9. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
10. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
11. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...your lifestyle may be to blame for you feeling dep...uals from 38 different states.// They found Americ...lue or depressed. Study participants who exercised...f depression. Researchers say their findings highl...
...eir recent discovery could be the first step in th...strophy. They say for the first time they have fou...all of the muscles in a mouse. Gene therapy for m...atment idea. However, finding a delivery method fo...
...a device that measures the stiffness of arteries m...and identify patients at risk for a stroke.// Res...atients were tested with a “blood-pressure-like” d...e leg as a way to determine artery stiffness. Pati...
...o opt for low-fat salad dressing anymore. New rese...ients found in vegetables.// Researchers studied ... consumed lettuce and other vegetables topped with... or 28 grams of canola oil. Blood tests were taken...
Other Medicine News:
(Date:10/6/2008)...nt of moderate to severe patients achieved endosco...oscopic remission at Week 10,in data from a 54-wee...ge,of Gastroenterology (ACG) Annual Scientific Mee...oday presented data from a,large, prospective stud...disease (CD) with a biologic compound. The data pr...
(Date:10/6/2008)...ther Product - Company,s Bioabsorbable Stent - Als..., Oct. 6 /- Data from multiple clinic...OrbusNeich,s Genous Bio-engineered R,stent, will b...ascular,Therapeutics symposium, TCT 2008, in Washi...he Academic Medical Center in,Amsterdam will provi...
(Date:10/3/2008)..., Oct. 3 /- deCODE genetics... investigational new drug,(IND) application for DG...of phosphodiesterase 4 (PDE4), with the US Food an... developed as a new and potentially safer means,of...e deficits associated,with Alzheimer,s disease and...
(Date:10/2/2008)...- Pharmaleads has obtained from the,F...to perform a single,ascending dose Phase I study w...neuropathic pain., Neuropathic pain is a major ch... in the world,s population of up to 6%, according ...as shingles, herpes, diabetes,antiviral or antitu...
Breaking Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2New method developed to identify genetic determinants of Alzheimers disease 1878 1New method developed to identify genetic determinants of Alzheimers disease 1878 2Stem Cells Modified to Home in Where Theyre Needed 9499 1Stem Cells Modified to Home in Where Theyre Needed 9499 2U S Food Safety 3A Home Grown Problems Abound 9497 1U S Food Safety 3A Home Grown Problems Abound 9497 2U S Food Safety 3A Home Grown Problems Abound 9497 3U S Food Safety 3A Home Grown Problems Abound 9497 4U S Food Safety 3A Home Grown Problems Abound 9497 5U S Food Safety 3A Home Grown Problems Abound 9497 6University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 9495 1University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 9495 2University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 9495 3
...omeostasis Effects in,Normal and Diabetic Rats --,...In a 14-day,Phase IIa study of the safety profile... dapagliflozin, a selective inhibitor of,the Sodiu... or,concomitantly with metformin in subjects with ...e events and no serious adverse,events were report...
...Is Commonly Seen In,Insulin Therapy , CHICAGO, Jun...sults of a new study that further demonstrated the...lin detemir [rDNA origin],injection). Patients wi...osage of Levemir® and achieve improvements in ...r primary care,physician. This improvement in A1c...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5
...ALPHA 10 System offers unparalleled image quality ...gonomically designed console., ,The ALPHA 10 i...al Medicine Specialists, large OB/GYN offices, Sur...aging departments in need of exceptional diagnosti...
...ly designed to fit the needs of a single facility ...From test initiation and processing to management ...a facilitates quick, efficient and precise laborat...rated and reside under a single database. Other fe...
CELL-DYN Sapphire, our flagship solution for high-volume laboratories, utilizes patented MAPSS plus 3-color fluorescent technology for improved lab efficiency.
Human growth hormone (hGH, somatotropin) is a polypeptide secreted by the anterior pituitary. It is 191 amino acids in length and has a molecular mass of approximately 22,000 daltons. Its metabolic
Medicine Products: